Literature DB >> 7649271

Identification of kappa- and delta-opioid receptor transcripts in immune cells.

C Gavériaux1, J Peluso, F Simonin, J Laforet, B Kieffer.   

Abstract

To investigate the role of opioids as direct modulators of the immune response, we have searched for expression of the recently cloned delta, mu and kappa opioid receptors in immune cells. We have devised a reverse transcriptase-polymerase chain reaction strategy which specifically detects a region spanning putative transmembrane regions 2 to 7 for each transcript in both human and mouse immune cells. In human peripheral blood lymphocyte and monocyte preparations, delta was undetectable while the kappa transcript was present. The analysis of human cell lines revealed low but significant levels of delta opioid receptor transcripts in T, B or monocyte cell lines while the kappa transcript was found in B cell lines only. Investigation of murine cells showed the presence of transcript for the delta receptor in splenocytes and in some T and B cell lines. Unexpectedly, no expression of the mu receptor was detected. Sequence analysis of PCR products demonstrated nucleotide identity between immune and neuronal transcripts, indicating that they derive from the same genes. In conclusion, our results lead to the identification of kappa and delta opioid receptor transcripts in immune cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649271     DOI: 10.1016/0014-5793(95)00766-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

Review 1.  Detection and function of opioid receptors on cells from the immune system.

Authors:  J M Bidlack
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 2.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

3.  Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.

Authors:  Matias Jaureguiberry-Bravo; Lillie Lopez; Joan W Berman
Journal:  J Leukoc Biol       Date:  2018-05-23       Impact factor: 4.962

4.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene.

Authors:  C Gavériaux-Ruff; H W Matthes; J Peluso; B L Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

6.  Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain.

Authors:  Elizabeth M Podhaizer; Shiping Zou; Sylvia Fitting; Kimberly L Samano; Nazira El-Hage; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-19       Impact factor: 4.147

7.  Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines.

Authors:  P Sacerdote; V E di San Secondo; G Sirchia; B Manfredi; A E Panerai
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

8.  Characterization of ionotropic glutamate receptors in human lymphocytes.

Authors:  G Lombardi; C Dianzani; G Miglio; P L Canonico; R Fantozzi
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

9.  Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum.

Authors:  D R Brown; S Poonyachoti; M A Osinski; T R Kowalski; M S Pampusch; R P Elde; M P Murtaugh
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

10.  Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae.

Authors:  Ying Lu; Terry A McNearney; Weidong Lin; Steven P Wilson; David C Yeomans; Karin N Westlund
Journal:  Mol Ther       Date:  2007-06-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.